\n<\/p>\n
ZURICH, SWITZERLAND – EQS Newswire –\u00a025 August 2021\u00a0–\u00a0Ad hoc announcement pursuant to Art. 53 LR\u00a0–\u00a0Achiko AG<\/a>\u00a0(SWX: ACHI, ISIN CH0522213468) through\u00a0PT Achiko Medika Indonesia<\/a>\u00a0(“Achiko”,
The approval opens the door to the rapid scale-up of
“We are proud and excited to receive the official
Covid-19 poses a challenge to traditional testing
Indofarma’s President Director, Arief Pramuhanto,
Dr Morris S. Berrie, President of Achiko, added:
In the cooperation between Achiko and Indofarma, a
Following the Ministry of Health’s approval for
Achiko, on product approval, has raised a total amount
“We’re grateful for the
AptameX\u2122, Achiko’s breakthrough DNA aptamer-based diagnostic
test for Covid-19, received product and registration emergency use approval
from the Ministry of Health in Indonesia, alongside its sister digital
passporting service, Teman Sehat\u2122\u00a0(“Health Buddy”). PT Achiko
Medika Indonesia, which is 50% owned by Achiko AG, and its manufacturing
partner, PT Indofarma TBK, have signed an agreement for …<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[60],"tags":[],"_links":{"self":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts\/17155"}],"collection":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/comments?post=17155"}],"version-history":[{"count":0,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts\/17155\/revisions"}],"wp:attachment":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/media?parent=17155"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/categories?post=17155"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/tags?post=17155"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nthe “Company”), is pleased to announce that the Ministry of Health of
\nthe Republic of Indonesia has granted product and registration approval for its
\nproprietary low-cost, rapid Covid-19 diagnostic test,\u00a0AptameX\u2122<\/a>, alongside its sister digital passporting
\nservice,\u00a0Teman Sehat\u2122<\/a>\u00a0(“Health Buddy”). Achiko’s
\n50%-subsidiary, PT Achiko Medika Indonesia, and\u00a0PT Indofarma TBK<\/a>\u00a0(“Indofarma) have
\nentered into an agreement to manufacture AptameX\u2122\u00a0and have received product registration approval
\nin Indonesia.<\/p>\n
\n
<\/p>\n
\nproduction and sale of Achiko’s AptameX\u2122\u00a0test kits in Indonesia. Available at an affordable price, AptameX\u2122\u00a0provides millions of Indonesian residents with
\naccess to accurate diagnostic testing for Covid-19, enabling the country to
\nmore effectively control and contain the pandemic. Indonesia passed 50,000
\ndaily Covid-19 cases in mid-July, amid the spread of the Delta variant in
\nSoutheast Asia.<\/p>\n
\n
<\/p>\n
\napproval for our breakthrough test kit AptameX\u2122. It is an immense achievement for us to be able to
\nmarket it with Indofarma,” said Steven Goh, CEO of Achiko. “At the
\nprojected vaccination rate, and considering likely mutations of the virus, the
\nnext few years may be very challenging not only for Indonesia, but also quite
\npossibly for the entire world. The combination of AptameX\u2122\u00a0and Teman Sehat\u2122\u00a0provides communities and governments with an
\naffordable, easy-to-use test and a digital passporting service, empowering them
\nin their fight against Covid-19 and all its variants.”<\/p>\n
\n
<\/p>\n
\nmethods, as low viral loads evade most rapid tests, calling for a new paradigm.
\nAptameX\u2122\u00a0uses a
\nproprietary, novel chemistry matching the speed of lateral flow rapid tests,
\nwhile improving on sensitivity. At a significantly lower price point than other
\ntests, it also offers a better user experience. Those that test positive are
\nalerted promptly through the Teman Sehat\u2122\u00a0digital passporting service and asked to follow local guidelines on
\nisolation and quarantine. Its affordability, scalability and superior
\nperformance make it an ideal tool in Indonesia’s fight against Covid-19.<\/p>\n
\n
<\/p>\n
\nexplains: “Testing regularly is crucial in containing the pandemic.
\nAptameX\u2122\u00a0is a
\nCovid-19 diagnostic test produced domestically by and for the people of
\nIndonesia that has been designed to be integrated into dental hygiene routines.
\nAccess to reliable and affordable testing will allow us to lead normal lives
\nagain and at the same time work to control the spread of Covid-19. Indofarma,
\nin partnership with Achiko, aims to make this diagnostic readily available at
\nan affordable price for everyone.”<\/p>\n
\n
<\/p>\n
\n“Our team has been tireless in developing our technologies for rapid,
\naffordable, diagnostic testing for Covid-19 and other forthcoming indications.
\nAptameX\u2122\u00a0is
\ndesigned to be easy to use and affordable, and therefore accessible to anyone.
\nWe believe AptameX\u2122\u00a0and our
\ndigital passporting service Teman Sehat\u2122\u00a0will be vital diagnostic resources for many years to come.”<\/p>\n
\n
<\/p>\n
\nmember of Indonesia’s Holding BUMN Farmasi, which is partly owned by the
\nGovernment of the Republic of Indonesia and listed on the Indonesia Stock
\nExchange (IDX: INAF), Achiko will provide the technology and all materials for
\ndiagnostic kits while Indofarma will carry out the production and product
\nregistration processes.<\/p>\n
\n
<\/p>\n
\nAptameX\u2122, Achiko is
\nlooking forward to securing a CE mark and introducing AptameX\u2122\u00a0and Teman Sehat\u2122\u00a0swiftly in further countries and regions. In
\nparallel, Achiko is also investigating applications of AptameX\u2122\u00a0to a range of other pathogenic diseases and
\ntherapeutic indications.<\/p>\n
\n
<\/p>\n
\nof CHF 3.45 million through share placement at an average price of CHF 0.192
\nper share to a leading Swiss venture capital group, OCS International
\nCommodities & Investments FZCO and other private investors. The funds are
\nto be used as working capital and production funds as well as for the
\nredemption of the Yorkville convertible note facility from 25 November 2020.<\/p>\n
\nsupport of all our investors and shareholders,” said Achiko CEO Goh.
\n“These most recent investments provide a solid platform to consolidate our
\nstrategy as a global leading diagnostics company, connecting our capabilities in
\nEurope and Asia in the fight against the challenge of Covid-19.”<\/p>\n<\/p><\/div>\n\n
Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"